切换至 "中华医学电子期刊资源库"

中华诊断学电子杂志 ›› 2013, Vol. 01 ›› Issue (01) : 57 -61. doi: 10.3877/cma.j.issn.2095-655X.2013.01.12

所属专题: 文献

临床研究

β-tubulin-Ⅲ、E-cadherin和α-catenin在乳腺癌及癌前病变中的表达及诊断意义
王刚平1,(), 张红2, 梁云爱1, 张作峰3, 袁宗怀3, 郭小艳1   
  1. 1. 276826 日照市人民医院 济宁医学院附属日照市人民医院病理科
    2. 276826 日照市人民医院 济宁医学院附属日照市人民医院科教科
    3. 276826 日照市人民医院 济宁医学院附属日照市人民医院乳腺外科
  • 收稿日期:2013-10-06 出版日期:2013-11-26
  • 通信作者: 王刚平
  • 基金资助:
    日照市应用技术研究与开发计划项目(2060402-4); 济宁医学院2013年度科研计划重点项目(JY2013KJ051)

The expressions and diagnostic significance of β-tubulin-Ⅲ, E-cadherin and α-catenin in precancerous Lesions and carcinoma of the breast

Gangping Wang1,(), Hong Zhang2, Yunai Liang1, Zuofeng Zhang3, Zonghuai Yuan3, Xiaoyan Guo1   

  1. 1. Department of Pathology, Rizhao People′s Hospital, Affiliated Rizhao People′s Hospital of Jining Medical College, Rizhao 276826, China
  • Received:2013-10-06 Published:2013-11-26
  • Corresponding author: Gangping Wang
  • About author:
    Corresponding author: Wang Gangping, Email:
引用本文:

王刚平, 张红, 梁云爱, 张作峰, 袁宗怀, 郭小艳. β-tubulin-Ⅲ、E-cadherin和α-catenin在乳腺癌及癌前病变中的表达及诊断意义[J/OL]. 中华诊断学电子杂志, 2013, 01(01): 57-61.

Gangping Wang, Hong Zhang, Yunai Liang, Zuofeng Zhang, Zonghuai Yuan, Xiaoyan Guo. The expressions and diagnostic significance of β-tubulin-Ⅲ, E-cadherin and α-catenin in precancerous Lesions and carcinoma of the breast[J/OL]. Chinese Journal of Diagnostics(Electronic Edition), 2013, 01(01): 57-61.

目的

探讨乳腺癌前病变及浸润性癌中β-tubulin-Ⅲ、E-cadherin和α-catenin的表达及诊断意义。

方法

采用免疫组织化学UltraSensitiveTM S-P法检测20例乳腺非典型导管上皮增生(ADH)、60例乳腺导管原位癌(DCIS)和90例浸润性乳腺癌(IDC)中的β-tubulin-Ⅲ、E-cadherin和α-catenin的表达,以30例正常乳腺组织作对照。

结果

β-tubulin-Ⅲ微管蛋白的表达:(1)β-tubulin-Ⅲ微管蛋白在正常对照组、ADH、DCIS和IDC组中表达率为22.0%,55.0%,71.7%,84.4%,4组间差异有统计学意义(χ2=22.298,P<0.05),两两组间比较,导管原位癌组、浸润性导管癌组与非典型导管增生组、正常对照组比较均差异有统计学意义(χ2=39.525,22.474,6.551,P<0.05)。2. E-cadherin和α-catenin的表达:在正常对照组、ADH、DCIS和IDC组中,E-cadherin的表达率分别为100%、75.0%、68.3%和41.1%,α-catenin的表达率为100.0%、80.0%、73.3%和56.7%,在四组中E-cadherin和α-catenin的表达差异有统计学意义(χ2=18.65,10.97,P<0.05)。

结论

乳腺癌前病变中β-tubulin-Ⅲ过表达,可能是乳腺癌形成的早期事件;E-cadherin和α-catenin在乳腺细胞过度增殖、恶性转化的过程中起重要作用,可作为判断组织病变程度及侵袭能力强弱的因素,β-tubulin-Ⅲ微管蛋白及E-cadherin、α-catenin有可能成为诊断和评估乳腺癌变和治疗的指标。

Objective

To explore the expression and diagnostic significance of β-tubulin-Ⅲ proteins, E-cadherin and α-catenin in breast precancerous lesions, including atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) and invasive ductal carcinomas (IDC).

Methods

The expressions of β-tubulin-Ⅲ, E-cadherin and α-catenin were investigated by immunhistochemical UltraSensitiveTM S-P method of precancerous Lesions including 20 cases of ADH, 60 cases of DCIS, and 90 cases of carcinoma of the breast. 30 cases of normal breast tissues were selected as a control group.

Results

(1)Significant differences of the β-tubulin-Ⅲ proteins expression were found among the four groups of normal breast tissues(20%), ADH(55.0%), DCIS(71.7%)and IDC(84.4%), (χ2=22.298, P<0.05), (P<0.05). (2)The expressions of E-cadherin and α-catenin in observed and controll groups: The expressions of E-cadherin in normal group, ADH, DCIS and IDC were 100%, 75.0%, 68.3% and 41.1%.The expressions of α-catenin in normal group, ADH, DCIS and IDC groups were 100%, 80.0%, 73.3% and 56.7%.There were significant differences of the expressions of E-cadherin and α-catenin between DCIS and IDC(χ2=18.650, 10.970, P<0.05).

Conclusions

Abnormal expression of β-tubulin-Ⅲ may be an early event in the development of breast tumor. The aberration of β-tubulin-Ⅲ may play a key role during oncogenesis and promote breast cellular transformation into malignancy. The abnormal expressions of E-cadherin and α-catenin with the degree of breast disease relates to the development, progression and metastasis of breast carcinoma, which may serve as one of the parameters for diagnosis of breast carcinoma and determine biological behavior and prognosis of breast carcinoma.

表1 受检者不同乳腺组织中β-tubulin-Ⅲ蛋白的表达
图1 E-cadherin和α-catenin在不同乳腺组织中的异常表达图像
表2 受检者不同乳腺组织中E-cadherin和α-catenin的表达(例数)
[1]
Lakhani SR,Ellis IO,Schnitt SJ, et al.WHO classification of tumours of the breast [M]. Lyon, France: IARC Press, 2012.
[2]
Wang GP,Zhang H,Zhang ZF, et al.Clinical and pathological characteristics of intraductal proliferative lesions and coexist with invasive ductal carcinomas [J]. Chinses-German J Clin Oncol, 2013, 12(12): 574-580.
[3]
王刚平,梁云爱,张作峰, 等. CD105标记MVD及HIF-1α在乳腺癌及癌前病变中的表达及意义[J/CD]. 中华临床医师杂志(电子版), 2013, 7(16): 7386-7391.
[4]
冯俊,李建军,应荣彪, 等. βⅢ-微管蛋白在乳腺癌癌变不同阶段的表达及意义[J/CD]. 中华临床医师杂志(电子版), 2011, 5(8): 2197-2200.
[5]
李广慧.E-cadherin和α-catenin在乳腺浸润性导管癌及乳腺癌前病变中的表达及意义[D].大连:大连医科大学.2008.
[6]
Tanaka K,Iwamoto S,Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas[J]. Clin Cancer Res, 2000, 6(1): 127-134.
[7]
Jawhari A,Jordan S,Poole S, et al.Abnormal immuneoreactivity of the E-cadherin/ catenin complex in gastric carcinoma:relationship with patient survival[J]. Gastroenterology, 1997, 112(1): 46-54.
[8]
Kausilia K,Krishandath,Hugow, et al.Reduced expression of the cadherin complex in oesopnageal adenocarcinoma correcateswith poor prognosis[J]. J Pathol , 1997, 182: 3.
[9]
Gritsko T,Williams A,Turkson J, et al.Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells[J]. Clin Cancer Res, 2006, 12(1): 11-19.
[10]
冶俊玲,韩静绮,郭新建, 等. 食管鳞癌组织中β微管蛋白Ⅲ、Stathmin和P糖蛋白的表达与预后[J]. 世界华人消化杂志, 2012, 20(27): 2613-2617.
[11]
Kam Y,Quaranta V. Cadherin-bound β-catenin feeds into the Wnt pathway upon adherens junctions dissociation: evidence for an intersection between β-catenin pools[J]. PLoS ONE, 2009, 4(2): e4580.
[12]
Hulpiau P,Roy FV.Molecular evolution of the cadherin superfamily[J]. Znt Biochem Cell Biol, 2009, 41(2): 349-369.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[3] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[8] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[9] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[10] 葛睿, 陈飞, 李杰, 李娟娟, 陈涵. 多基因检测在早期乳腺癌辅助治疗中的应用价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 257-263.
[11] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[13] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[14] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[15] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
阅读次数
全文


摘要